IRIS
FERRARO, Giuseppa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.267
EU - Europa 1.493
AS - Asia 1.073
SA - Sud America 332
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.226
SG - Singapore 434
SE - Svezia 401
IE - Irlanda 353
CN - Cina 344
BR - Brasile 298
HK - Hong Kong 136
DE - Germania 134
IT - Italia 110
UA - Ucraina 100
FR - Francia 79
FI - Finlandia 69
PL - Polonia 66
GB - Regno Unito 60
RU - Federazione Russa 49
VN - Vietnam 42
IN - India 29
BE - Belgio 18
CA - Canada 18
AT - Austria 17
AR - Argentina 14
BD - Bangladesh 14
MX - Messico 12
ZA - Sudafrica 11
IQ - Iraq 10
NL - Olanda 10
ID - Indonesia 9
TR - Turchia 9
MA - Marocco 8
CO - Colombia 7
JP - Giappone 6
AE - Emirati Arabi Uniti 5
PK - Pakistan 5
DZ - Algeria 4
EC - Ecuador 4
ES - Italia 4
JM - Giamaica 4
JO - Giordania 4
UZ - Uzbekistan 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
IL - Israele 3
LT - Lituania 3
LV - Lettonia 3
PE - Perù 3
RS - Serbia 3
SA - Arabia Saudita 3
VE - Venezuela 3
AL - Albania 2
AZ - Azerbaigian 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
IR - Iran 2
OM - Oman 2
PA - Panama 2
PH - Filippine 2
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
KE - Kenya 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.195
Salva come PNG Salva come JPEG
Città #
Dublin 352
Chandler 309
Ashburn 289
Dallas 240
Singapore 224
Nyköping 205
Jacksonville 196
Beijing 156
Hong Kong 136
New York 76
Ann Arbor 63
The Dalles 61
Warsaw 61
Dearborn 58
Los Angeles 58
Cambridge 51
Princeton 51
Medford 49
Des Moines 42
Messina 41
Munich 41
Boardman 34
Buffalo 30
Jinan 25
Woodbridge 22
São Paulo 21
Tianjin 19
Brussels 18
Pune 17
San Mateo 17
Vienna 17
Lancaster 16
Frankfurt am Main 15
Ho Chi Minh City 15
Shenyang 14
Turku 14
Belo Horizonte 13
Wilmington 13
Redondo Beach 12
Nanjing 11
Brooklyn 10
Hebei 10
Zhengzhou 10
Houston 9
Johannesburg 9
Montreal 9
Atlanta 7
Campinas 7
Chicago 7
Dong Ket 7
Rio de Janeiro 7
Amsterdam 6
Goiânia 6
Grammichele 6
Guangzhou 6
Jakarta 6
London 6
Mexico City 6
Ningbo 6
San Francisco 6
Taizhou 6
Augusta 5
Baghdad 5
Brasília 5
Changsha 5
Dhaka 5
Fort Washington 5
Helsinki 5
Joinville 5
Manchester 5
Washington 5
Curitiba 4
Da Nang 4
Denver 4
Fuzhou 4
Haikou 4
Hanoi 4
Lanzhou 4
Leawood 4
Roubaix 4
Seattle 4
Stockholm 4
Tashkent 4
Tokyo 4
Amman 3
Ankara 3
Auburn Hills 3
Belgrade 3
Boston 3
Brockport 3
Casablanca 3
Catania 3
Chennai 3
Düsseldorf 3
Guarulhos 3
Hangzhou 3
Hyderabad 3
Jiaxing 3
Juiz de Fora 3
Maceió 3
Totale 3.404
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 174
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 168
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 159
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 155
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 136
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 132
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 124
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 124
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 123
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 122
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 121
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 118
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 116
Beta=interferon in the treatment of 14 patie nts with advanced colorectal carcinoma. J Exp Pathol. 1987 Summer;3(4):603-5. No abstract available. PMID: 3454807 [PubMed - indexed for MEDLINE] 114
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 114
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 113
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 113
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 109
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 108
NSCLC and HER2: between lights and shadows 107
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 104
Metastasis risk assessment in breast cancer (BC): a preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes 103
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients 102
Correlation between serum magnesium levels and skin toxicity during cetuximab treatment in squamous cell carcinoma of head and neck cancer (SCCHN): the role of weekly intravenous magnesium supplementation. 102
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. 101
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 96
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 95
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 94
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 93
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 93
RANDOMISED PHASE II TERTIARY CHEMOPREVENTION TRIAL FOR COLORECTAL ADENOMA IN 24 PATIENTS WITH COLORECTAL CANCER TREATED WITH CELECOXIB 92
Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients 87
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 87
Effectiveness of the combination therapy with lisinopril, ivabradine and multivitamin supplementation in anthracycline-induced severe cardiotoxicity 86
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 86
Early Breast Cancer HER2 positivo in postmenopausa: strategia terapeutica adiuvante 85
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 85
Uncommon breast metastatic site and eribulin responsiveness in a heavily pretreated patient 84
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 82
Neoplasie della testa collo nell’ anziano 78
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 77
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 76
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 76
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 74
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 71
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 70
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 70
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 61
Invecchiamento e cancro. 59
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 59
null 52
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 38
null 37
null 33
null 22
Totale 5.260
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.423
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021219 0 0 0 0 0 44 17 25 15 39 53 26
2021/2022412 2 66 10 11 14 6 23 9 5 99 57 110
2022/20231.137 87 118 49 105 83 104 18 88 444 2 29 10
2023/2024313 18 50 15 27 16 124 30 17 0 4 1 11
2024/20251.030 8 9 19 68 47 42 12 181 268 60 98 218
2025/20261.138 181 197 243 186 289 42 0 0 0 0 0 0
Totale 5.260